Advertisement
Singapore markets open in 18 minutes

  • Straits Times Index

    3,292.69
    +10.64 (+0.32%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • Dow

    37,903.29
    +87.37 (+0.23%)
     

  • Nasdaq

    15,605.48
    -52.34 (-0.33%)
     

  • Bitcoin USD

    57,803.77
    -2,364.58 (-3.93%)
     

  • CMC Crypto 200

    1,273.64
    -65.43 (-4.88%)
     

  • FTSE 100

    8,121.24
    -22.89 (-0.28%)
     

  • Gold

    2,333.10
    +22.10 (+0.96%)
     

  • Crude Oil

    79.21
    +0.21 (+0.27%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • Nikkei

    38,112.82
    -161.23 (-0.42%)
     

  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     

  • FTSE Bursa Malaysia

    1,575.97
    -6.69 (-0.42%)
     

  • Jakarta Composite Index

    7,234.20
    -7,155.78 (-49.73%)
     

  • PSE Index

    6,700.49
    -69.15 (-1.02%)
     

DiaSorin confirms 2023 guidance after Q1 results

Reuters
·1-min read

(Reuters) - Italian medical diagnostics group DiaSorin said on Wednesday it had reported a decline in revenue in the first quarter, after demand in COVID-related business sharply dropped as pandemics effects faded away.

Q1 revenue plunged 20.6% year-on-year to 289.6 million euros ($318.79 million), leading to a 40.6% shrink in net profit, which came in at 41.7 million euros, the company said in a note.

Revenue from COVID-related business unit dropped 78.5% in the first quarter, in line with an expected 75% decrease year-on year. Net of this unit and molecular respiratory business, revenue grew 3% at constant perimeter.

DiaSorin confirmed its 2023 guidance for the full year, which sees total revenue down 14% on a yearly basis.

($1 = 0.9084 euros)

(Reporting by Alberto Chiumento in Gdansk; Editing by Cristina Carlevaro)